Dengue Vaccines
Current Topics in Microbiology and Immunology · 2025
DOI: 10.1007/82_2025_320 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Topics in Microbiology and Immunology, 2025. Verfasst von Silvia Beatriz Boscardin. Beteiligte Einrichtung: Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. sbboscardin@usp.br. Hauptthemen laut MEDLINE: Dengue Vaccines, Dengue, Dengue Virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 151 Literaturangaben.
Abstract (Originalsprache)
This chapter offers an overview of dengue vaccines that have advanced to clinical trials, addressing the intricate challenges in their development. It details the complexities of the dengue virus, including its four serotypes and the phenomenon of antibody-dependent enhancement (ADE), which significantly impacts vaccine design. The chapter reviews the historical trajectory and current landscape of vaccine candidates, such as Dengvaxia®, Qdenga®, and Butantan-DV, analyzing their efficacy, safety profiles, and the lessons learned from their clinical trials. It also discusses other hurdles like suitable animal models and viral interference. Ultimately, the chapter highlights the advancements made and outlines future research directions crucial for a universally effective dengue vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. sbboscardin@usp.br.
Zitieren
APA
Boscardin, S. B. (2025). Dengue Vaccines. Current Topics in Microbiology and Immunology. https://doi.org/10.1007/82_2025_320
Vancouver
Boscardin SB. Dengue Vaccines. Current Topics in Microbiology and Immunology. 2025. doi:10.1007/82_2025_320
BibTeX
@article{Boscardin2025,
author = {Boscardin, Silvia Beatriz},
title = {Dengue Vaccines},
journal = {Current Topics in Microbiology and Immunology},
year = {2025},
doi = {10.1007/82_2025_320}
}
EUVIMED